Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Researchers sought to determine whether patients with PMBCL may be able to forgo irradiation therapy during consolidation.

Axicabtagene ciloleucel had durable responses, long-term survival, and consistent outcomes in patients with relapsed or ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...